Is it mandatory that the grid box has to be localized specifically at the same exact site where the reported inhibitor binds to the receptor? Is there any relevance for carrying out blind docking for a new drug (ligand) against a protein when already the site of inhibitor and protein binding is known from experimental XRD structure.